IMA
ImageneBio Inc
Biotechnology
Market Cap$61M
5Y Perf.-98.4%
Build Your Comparison
Side-by-side financial analysisIMA
PRTA
FOLD
IMVT
Try popular comparisons:
Stock Comparison
IMA vs PRTA vs FOLD vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
PRTA
Prothena Corporation plc
Biotechnology
Market Cap$432M
5Y Perf.-67.2%
FOLD
Amicus Therapeutics, Inc.
Biotechnology
Market Cap$4.55B
5Y Perf.+46.4%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$6.90B
5Y Perf.+109.6%
IMA vs PRTA vs FOLD vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  IMA |  PRTA |  FOLD |  IMVT |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $61M | $432M | $4.55B | $6.90B |
| Revenue (TTM) | $0.00 | $58M | $634M | $0.00 |
| Net Income (TTM) | $-45M | $-151M | $-27M | $-506M |
| Gross Margin | -29.1% | 46.8% | 87.9% | — |
| Operating Margin | -60.6% | -217.9% | 5.2% | — |
| Forward P/E | — | 176.7x | 40.6x | — |
| Total Debt | $10M | $14M | $483M | $72K |
| Cash & Equiv. | $35M | $308M | $214M | $902M |
IMA vs PRTA vs FOLD vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IMA
PRTA
FOLD
IMVT
| Stock | Mar 21 | Jun 26 | Return |
|---|---|---|---|
| ImageneBio Inc (IMA) | 100 | 1.6 | -98.4% |
| Prothena Corporatio… (PRTA) | 100 | 32.8 | -67.2% |
| Amicus Therapeutics… (FOLD) | 100 | 146.4 | +46.4% |
| Immunovant, Inc. (IMVT) | 100 | 209.6 | +109.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IMA vs PRTA vs FOLD vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: FOLD leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Immunovant, Inc. is the stronger pick specifically for profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
🥇FOLD emerged as the overall leader. Track its performance:
IMA
ImageneBio Inc
The Defensive Pick
IMA is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.83, Low D/E 7.5%, current ratio 12.49x
- Beta 0.83, current ratio 12.49x
Best for: sleep-well-at-night and defensive
PRTA
Prothena Corporation plc
The Secondary Option
PRTA lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
FOLD
Amicus Therapeutics, Inc.
The Income Pick
FOLD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.48
- Rev growth 20.0%, EPS growth 51.2%, 3Y rev CAGR 24.4%
- 20.0% revenue growth vs PRTA's -92.8%
- Better valuation composite
Best for: income & stability and growth exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 237.9% 10Y total return vs FOLD's 147.3%
- 2.6% margin vs IMA's -56.7%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  FOLD | 20.0% revenue growth vs PRTA's -92.8% |
| Value | FOLD | Better valuation composite |
| Quality / Margins |  IMVT | 2.6% margin vs IMA's -56.7% |
| Stability / Safety | FOLD | Beta 0.48 vs IMVT's 1.66 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | FOLD | +134.8% vs IMA's -67.0% |
| Efficiency (ROA) | FOLD | -3.2% ROA vs IMVT's -62.2% |
IMA vs PRTA vs FOLD vs IMVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
Segment breakdown not available.
Segment breakdown not available.
IMA vs PRTA vs FOLD vs IMVT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLFOLDLAGGINGPRTA
Who Leads Where
FOLD leads in 4 of 6 categories
IMVT leads 1 • IMA leads 0 • PRTA leads 0
Explore the data ↓PRTAProthena Corporation …
0leads
IMAImageneBio Inc
0leads
IMVTImmunovant, Inc.
1leads
FOLDAmicus Therapeutics, …
4leads
6 Total Categories
CATEGORYLEADERvs IMVTvs IMAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
FOLD4/6
Valuation MetricsMultiples, price ratios, and targets
FOLD3/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
FOLD6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
FOLD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
FOLD leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
FOLD and IMVT operate at a comparable scale, with $634M and $0 in trailing revenue. FOLD is the more profitable business, keeping -4.3% of every revenue dollar as net income compared to IMA's -56.7%. On growth, PRTA holds the edge at +17.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric |  IMAImageneBio Inc |  PRTAProthena Corporat… | FOLDAmicus Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $58M | $634M | $0 |
| EBITDAEarnings before interest/tax | -$53M | -$124M | $40M | -$532M |
| Net IncomeAfter-tax profit | -$45M | -$151M | -$27M | -$506M |
| Free Cash FlowCash after capex | -$52M | -$81M | $30M | -$407M |
| Gross MarginGross profit ÷ Revenue | -29.1% | +46.8% | +87.9% | — |
| Operating MarginEBIT ÷ Revenue | -60.6% | -2.2% | +5.2% | — |
| Net MarginNet income ÷ Revenue | -56.7% | -2.6% | -4.3% | — |
| FCF MarginFCF ÷ Revenue | -59.8% | -140.6% | +4.7% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +17.1% | +23.7% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -4.3% | +153.6% | -89.0% | -14.1% |
FOLD leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
FOLD leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
| Metric | IMAImageneBio Inc | PRTAProthena Corporat… | FOLDAmicus Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| Market CapShares × price | $61M | $432M | $4.5B | $6.9B |
| Enterprise ValueMkt cap + debt − cash | $36M | $138M | $4.8B | $6.0B |
| Trailing P/EPrice ÷ TTM EPS | -0.50x | -1.82x | -164.85x | -12.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 176.66x | 40.62x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 114.88x | — |
| Price / SalesMarket cap ÷ Revenue | 76.54x | 44.60x | 7.17x | — |
| Price / BookPrice ÷ Book value/share | 0.20x | 1.58x | 16.29x | 7.19x |
| Price / FCFMarket cap ÷ FCF | — | — | 152.43x | — |
FOLD leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
FOLD leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
FOLD delivers a -12.0% return on equity — every $100 of shareholder capital generates $-12 in annual profit, vs $-68 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to FOLD's 1.76x. On the Piotroski fundamental quality scale (0–9), FOLD scores 4/9 vs PRTA's 1/9, reflecting mixed financial health.
| Metric | IMAImageneBio Inc | PRTAProthena Corporat… | FOLDAmicus Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -35.2% | -49.9% | -12.0% | -68.2% |
| ROA (TTM)Return on assets | -31.3% | -42.3% | -3.2% | -62.2% |
| ROICReturn on invested capital | -35.9% | -21.0% | +5.3% | — |
| ROCEReturn on capital employed | -35.6% | -47.0% | +5.1% | -68.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.08x | 0.05x | 1.76x | 0.00x |
| Net DebtTotal debt minus cash | -$25M | -$294M | $269M | -$902M |
| Cash & Equiv.Liquid assets | $35M | $308M | $214M | $902M |
| Total DebtShort + long-term debt | $10M | $14M | $483M | $72,000 |
| Interest CoverageEBIT ÷ Interest expense | -560.22x | — | 1.00x | — |
FOLD leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $31,304 today (with dividends reinvested), compared to $330 for IMA. Over the past 12 months, FOLD leads with a +134.8% total return vs IMA's -67.0%. The 3-year compound annual growth rate (CAGR) favors IMVT at 15.7% vs IMA's -59.4% — a key indicator of consistent wealth creation.
| Metric | IMAImageneBio Inc | PRTAProthena Corporat… | FOLDAmicus Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -19.7% | -10.3% | +1.5% | +29.8% |
| 1-Year ReturnPast 12 months | -67.0% | +62.7% | +134.8% | +110.9% |
| 3-Year ReturnCumulative with dividends | -93.3% | -88.7% | +11.6% | +55.0% |
| 5-Year ReturnCumulative with dividends | -96.7% | -82.7% | +35.2% | +213.0% |
| 10-Year ReturnCumulative with dividends | -98.6% | -82.0% | +147.3% | +237.9% |
| CAGR (3Y)Annualised 3-year return | -59.4% | -51.7% | +3.7% | +15.7% |
IMVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
FOLD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FOLD is the less volatile stock with a 0.48 beta — it tends to amplify market swings less than IMVT's 1.66 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs IMA's 30.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IMAImageneBio Inc | PRTAProthena Corporat… | FOLDAmicus Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.83x | 1.50x | 0.48x | 1.66x |
| 52-Week HighHighest price in past year | $18.00 | $11.80 | $14.50 | $36.27 |
| 52-Week LowLowest price in past year | $1.36 | $4.95 | $5.51 | $14.32 |
| % of 52W HighCurrent price vs 52-week peak | +30.2% | +69.9% | +99.9% | +92.7% |
| RSI (14)Momentum oscillator 0–100 | 51.8 | 35.6 | 72.2 | 57.9 |
| Avg Volume (50D)Average daily shares traded | 432K | 447K | 2.3M | 1.9M |
FOLD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: PRTA as "Buy", FOLD as "Buy", IMVT as "Buy". Consensus price targets imply 130.3% upside for PRTA (target: $19) vs 0.1% for FOLD (target: $15).
| Metric | IMAImageneBio Inc | PRTAProthena Corporat… | FOLDAmicus Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $19.00 | $14.50 | $43.67 |
| # AnalystsCovering analysts | — | 28 | 24 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
FOLD leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). IMVT leads in 1 (Total Returns).
Best OverallAmicus Therapeutics, Inc. (FOLD)Leads 4 of 6 categories
Loading custom metrics...
IMA vs PRTA vs FOLD vs IMVT: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is IMA or PRTA or FOLD or IMVT a better buy right now?
For growth investors, Amicus Therapeutics, Inc.
(FOLD) is the stronger pick with 20. 0% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Analysts rate Prothena Corporation plc (PRTA) a "Buy" — based on 28 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IMA or PRTA or FOLD or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +213. 0%, compared to -96. 7% for ImageneBio Inc (IMA). Over 10 years, the gap is even starker: IMVT returned +237. 9% versus IMA's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IMA or PRTA or FOLD or IMVT?
By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.
(FOLD) is the lower-risk stock at 0. 48β versus Immunovant, Inc. 's 1. 66β — meaning IMVT is approximately 243% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — IMA or PRTA or FOLD or IMVT?
By revenue growth (latest reported year), Amicus Therapeutics, Inc.
(FOLD) is pulling ahead at 20. 0% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Amicus Therapeutics, Inc. grew EPS 51. 2% year-over-year, compared to -954. 9% for ImageneBio Inc. Over a 3-year CAGR, FOLD leads at 24. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — IMA or PRTA or FOLD or IMVT?
Immunovant, Inc.
(IMVT) is the more profitable company, earning 0. 0% net margin versus -56. 7% for ImageneBio Inc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FOLD leads at 5. 4% versus -60. 6% for IMA. At the gross margin level — before operating expenses — FOLD leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is IMA or PRTA or FOLD or IMVT more undervalued right now?
On forward earnings alone, Amicus Therapeutics, Inc.
(FOLD) trades at 40. 6x forward P/E versus 176. 7x for Prothena Corporation plc — 136. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRTA: 130. 3% to $19. 00.
07Which pays a better dividend — IMA or PRTA or FOLD or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is IMA or PRTA or FOLD or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Amicus Therapeutics, Inc.
(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48), +147. 3% 10Y return). Prothena Corporation plc (PRTA) carries a higher beta of 1. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FOLD: +147. 3%, PRTA: -82. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between IMA and PRTA and FOLD and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: IMA is a small-cap quality compounder stock; PRTA is a small-cap quality compounder stock; FOLD is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.